MakeMyTrip Ltd (MMYT) Stock Price Today
Aura AI Summary
Key Stats
- $4.38BMarket Cap
- 1,317,205Volume
- Consumer CyclicalSector
- $90.7352W High
- $36.3052W Low
- 12 DaysTypical Hold Time
- $5.04BEnterprise Value
- -Div Yield
- -Trading Activity
Track MakeMyTrip Ltd (MMYT) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, MakeMyTrip Ltd has traded between a low of $36.3 and a high of $90.73, highlighting its annual price range. Buy and sell MakeMyTrip Ltd shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Most Recent News
JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026
JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...

Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.
Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...

Clinical trial supplies market to nearly double from $5.7B in 2025 to $10.7B by 2033, driven by biologics and decentralized trials
The global clinical trial supplies market is projected to grow from $5.7 billion in 2025 to $10.7 billion by 2033, at an 8.4% CAGR. This growth is driven by increased R&D investments, rising chronic diseases, and the expansion of biologics, personali...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.